Mesothelioma Patients Should Use Caution When Considering Complementary Treatments

Mesothelioma Complementary Treatments

If you are going to consider complementary therapies for malignant mesothelioma, it may not be wise to do it at the exclusion of conventional cancer treatment. That is the message from a new study of nearly 2 million cancer patients published in JAMA Oncology. The study included patients with breast, prostate, lung, or colorectal cancer who were diagnosed between 2004 and 2013 at 1,500 Commission on Cancer-accredited centers across the US. Researchers found that the 258 patients who chose to use complementary medicine for their condition had a higher risk of death than those who didn’t. But the reason may have less to do with the complementary therapies themselves than the fact that many of these same patients also refused … Continue reading Mesothelioma Patients Should Use Caution When Considering Complementary Treatments »

New Study Sheds Light on Genetic Origins of Malignant Mesothelioma

Scientists in Australia have made a big step forward in understanding how a genetic mutation appears to drive the development of cancers such as malignant mesothelioma. The gene in question is called p53. Also known as the “guardian of the genome” for its tumor-suppressing action, p53 has been found to be mutated in about half of all human cancers, including many cases of mesothelioma. Although the primary external cause of mesothelioma is exposure to asbestos, the mutated p53 gene helps explain why some asbestos-exposed cells suddenly become cancerous and are able to grow and spread, unchecked. It may also help scientists develop new, more effective mesothelioma treatments. Right now, the prognosis for mesothelioma is often very poor. The p53 Gene … Continue reading New Study Sheds Light on Genetic Origins of Malignant Mesothelioma »

This Subset of Mesothelioma Patients May Live Longer

A group of mesothelioma experts from around the world has identified a set of criteria linked with longer mesothelioma survival. They are hopeful that their research will help doctors identify mesothelioma patients who fall into this longer-living group and direct them to the special care they may need to stay healthier, longer. In a new article in the Journal of Clinical Oncology, some of the world’s leading mesothelioma researchers, including scientists from Stanford University, New York University Langone Medical Center, The University of Hawaii, the Hyogo College of Medicine in Japan, and the Mesothelioma Applied Research Foundation, say mesothelioma patients who meet these criteria should consider genetic counseling and cancer screening. Criteria for Improved Mesothelioma Outcomes The report was based … Continue reading This Subset of Mesothelioma Patients May Live Longer »

Ofev Fails to Boost Mesothelioma Survival in New Study

In the quest to develop new, more effective first-line treatments for malignant pleural mesothelioma, it now looks like Ofev (nintedanib) is out of the running. Phase III results of the LUME-Meso mesothelioma trial are in and they contain some disappointing news for mesothelioma patients and for the drug’s developer, Boehringer Ingelheim. The news is especially disappointing since the results of the Phase II portion of the trial, released last year, looked promising. At that time, researchers reported a survival gain of more than 5 months among the Ofev-treated mesothelioma patients and progression-free survival of four months. But further research did not support those results, as investigators announced to the world’s lung cancer experts at the IASLC 19th World Lung Cancer … Continue reading Ofev Fails to Boost Mesothelioma Survival in New Study »

A Less Formal Approach to Connecting Mesothelioma Patients and Researchers

immunotherapy research

Mesothelioma researchers in England are experimenting with an innovative way to connect patients and scientists in the quest for a cure. Malignant mesothelioma, the cancer most closely associated with asbestos exposure, is one of the world’s most deadly malignancies. Many patients diagnosed with mesothelioma are given only months to live. Increasingly, clinical research holds great promise for new ways of approaching diseases like mesothelioma, but understanding that research and its implications can be difficult, even when listening to the researchers directly. To bridge the gap, investigators with the June Hancock Mesothelioma Research Fund (JHMRF) in Sheffield, UK have introduced “Meet the Researchers” — a program designed to engage mesothelioma patients and researchers in a more informal way. Mesothelioma Research Can … Continue reading A Less Formal Approach to Connecting Mesothelioma Patients and Researchers »

How Doctors Break Bad News May Impact Mesothelioma Survival

For newly diagnosed mesothelioma patients, having a doctor who is too compassionate could have a negative impact on their survival. Researchers at France’s University of Lille made that seemingly counterintuitive observation as part of the first study of the prognostic role of physician empathy in cancer patients. The results, published in the Journal of Clinical Medicine, suggest that, rather than comforting patients, too much compassion and listening from the oncologist tends to make them worry more about their odds of survival. Physician Attitude and Mesothelioma Outcomes The study involved 179 patients who were diagnosed with lung cancer or pleural mesothelioma between January 2015 and March 2016. Both cancers are difficult to treat and often carry a poor prognosis. This is … Continue reading How Doctors Break Bad News May Impact Mesothelioma Survival »

Old Drug May Breath New Life Into Mesothelioma Radiotherapy

Researchers at the University of Ohio may have found a way to make radiation therapy more effective for people with mesothelioma and other types of solid tumors. They’re using a muscle relaxant approved in the 1800s to increase the level of oxygen in cancer cells and make them more susceptible to the damaging effects of radiation. The research could have wide-ranging implications, especially for patients fighting treatment-resistant malignancies like pleural mesothelioma. The Limitations of Radiation for Pleural Mesothelioma Mesothelioma is a fast-growing cancer associated with asbestos exposure that occurs on the membranes around internal organs. Although the irregular shape and tricky location of mesothelioma tumors can make them difficult to treat with radiotherapy, advanced targeting techniques are making it more … Continue reading Old Drug May Breath New Life Into Mesothelioma Radiotherapy »

New Data Suggest a Mesothelioma Blood Test is Possible

A new technology that looks for genetic material from cancer cells in the blood could open the door to the fastest, easiest way yet to diagnose early malignant pleural mesothelioma. The test, which has already shown potential for early detection of lung cancer, was developed by a California-based life sciences company called GRAIL. GRAIL-funded researchers shared the data on the test at the American Society of Clinical Oncology annual meeting this summer in Chicago. The results are part of the preliminary data from the company’s ongoing Circulating Cell-Free Genome Atlas study, a huge study on cancer diagnosis that aims to enroll 15,000 people (70 percent with cancer and 30 percent without) from 141 sites in the US and Canada. “We’re … Continue reading New Data Suggest a Mesothelioma Blood Test is Possible »

Lung Fluid Proteins Could be Key to Earlier Mesothelioma Diagnosis

Australian researchers say proteins found in lung fluid could hold the key to diagnosing pleural mesothelioma months or even years before a tumor is visible on imaging scans. Proteins function as communication devices in the body, directing all sorts of critical cellular processes, including the processes that tell cancer cells to begin replicating at a higher rate than normal cells. Scientists at Flinders University, one of the world’s leaders in mesothelioma research, wondered if the proteins that help give rise to malignant pleural mesothelioma could be found in pleural effusions and used as biomarkers to identify the cancer earlier. Looking for Mesothelioma Biomarkers in Lung Fluid In a new study published in the Journal of Proteomics, the team notes that … Continue reading Lung Fluid Proteins Could be Key to Earlier Mesothelioma Diagnosis »

Mesothelioma Genetic “Fingerprint” Could Impact Compensation

A new report suggests that it may be possible to verify that a case of lung cancer or malignant mesothelioma was caused by exposure to asbestos. The key may lie in tiny cellular structures called  microRNAs. If the microRNA asbestos profile can be verified, it could have a significant impact on work-related compensation for pleural mesothelioma and asbestos-related lung cancer. The Molecular “Fingerprint” of Mesothelioma? MicroRNAs (miRNAs) are small non-coding molecules of RNA that play a key role in the regulation of gene expression in cells. When these miRNAs are out of balance or “overexpressed”, the result can be cancer. By examining the miRNAs of mesothelioma patients, lung cancer patients, and healthy subjects, researchers at Marche Polytechnic University in Ancona, Italy … Continue reading Mesothelioma Genetic “Fingerprint” Could Impact Compensation »

Get your free copy of
“Surviving Mesothelioma” Today!